Table 2. Hepatocellular carcinoma staging.

Abbreviations: BCLC, Barcelona-Clinic Liver Cancer; ECOG, Status Eastern Cooperative Oncology Group; MELD: Model for End-Stage Liver Disease; CLIP, Cancer of the Liver Italian Program

	All patients (n=32)	BCLC Stage C (n=9)	BCLC Stage D (n=23)
ECOG performance status
0	4 (12.5%)	1 (11.1%)	3 (13.0%)
1	18 (56.3%)	7 (77.7%)	11 (47.8%)
2	7 (21.9%)	0 (0.0%)	7 (30.4%)
3	3 (9.4%)	1 (11.1%)	2 (8.7%)
Child-Pugh
B	8 (25.0%)	1 (11.1%)	7 (30.4%)
C	24 (75.0%)	8 (88.9%)	16 (69.6%)
MELD score
1 to 5	1 (3.1%)	1 (11.1%)	0 (0.0%)
6 to 10	20 (62.5%)	4 (44.4%)	0 (0.0%)
11 to 15	7 (21.9%)	2 (22.2%)	16 (69.6%)
>15	3 (9.4%)	1 (11.1%)	5 (21.7%)
Missing	1 (3.1%)	1 (11.1%)	2 (8.7%)
Okuda stage
I (no factors present)	18 (56.3%)	5 (55.5%)	13 (56.5%)
II (1 to 2 factors present)	12 (37.5%)	3 (33.3%)	9 (39.1%)
III (3 to 4 factors present)	1 (3.1%)	0 (0.0%)	1 (4.3%)
Missing	1 (3.1%)	1 (11.1%)	0 (0.0%)
CLIP score
1	1 (3.1%)	1 (11.1%)	0 (0.0%)
2	11 (34.4%)	2 (22.2%)	16 (69.6%)
3	15 (46.8%)	5 (55.5%)	5 (21.7%)
4 or more	4 (12.5%)	0 (0.0%)	2 (8.7%)
Missing	1 (3.1%)	1 (11.1%)
Milan criteria
Yes	16 (50.0%)	3 (33.3%)	13 (56.5%)
No	15 (46.9%)	5 (55.5%)	10 (43.5%)
Missing	1 (3.1%)	1 (11.1%)	0 (0.0%)